Quiescent fibroblasts possess unique genetic program and exhibit high metabolic activity distinct from proliferative fibroblasts. In response to inflammatory stimulation, quiescent fibroblasts are more active in expressing cyclooxygenase-2 and other proinflammatory genes than proliferative fibroblasts. The underlying transcriptional mechanism is unclear. Here we show that phorbol 12-myristate 13-acetate (PMA) and cytokines increased p300 histone acetyltransferase activity to a higher magnitude (> 2 fold) in quiescent fibroblasts than in proliferative fibroblasts. Binding of p300 to cyclooxygenase-2 promoter was reduced in proliferative fibroblasts. By ultrahigh-performance liquid chromatography coupled with a quadrupole time of flight mass spectrometer and enzyme-immunoassay, we found that production of 5-methoxytryptophan was 2–3 folds higher in proliferative fibroblasts than that in quiescent fibroblasts. Addition of 5-methoxytryptophan and its metabolic precursor, 5-hydroxytryptophan, to quiescent fibroblasts suppressed PMA-induced p300 histone acetyltransferase activity and cyclooxygenase-2 expression to the level of proliferative fibroblasts. Silencing of tryptophan hydroxylase-1 or hydroxyindole O-methyltransferase in proliferative fibroblasts with siRNA resulted in elevation of PMA-induced p300 histone acetyltransferase activity to the level of that in quiescent fibroblasts, which was rescued by addition of 5-hydroxytryptophan or 5-methoxytryptophan. Our findings indicate that robust inflammatory gene expression in quiescent fibroblasts vs. proliferative fibroblasts is attributed to uncontrolled p300 histone acetyltransferase activation due to deficiency of 5-methoxytryptophan production. 5-methoxytryptophan thus is a potential valuable lead compound for new anti-inflammatory drug development.
References
[1]
Coller HA, Sang L, Roberts JM (2006) A new description of cellular quiescence. PLoS Biol 4: e83. doi: 10.1371/journal.pbio.0040083
[2]
Lemons JM, Feng XJ, Bennett BD, Legesse-Miller A, Johnson EL, et al. (2010) Quiescent fibroblasts exhibit high metabolic activity. PLoS Biol 8: e1000514. doi: 10.1371/journal.pbio.1000514
[3]
Chen BR, Cheng HH, Lin WC, Wang KH, Liou JY, et al. (2012) Quiescent fibroblasts are more active in mounting robust inflammatory responses than proliferative fibroblasts. PLoS One 7: e49232. doi: 10.1371/journal.pone.0049232
[4]
Gilroy DW, Saunders MA, Sansores-Garcia L, Matijevic-Aleksic N, Wu KK (2001) Cell cycle-dependent expression of cyclooxygenase-2 in human fibroblasts. FASEB J 15: 288–290.
[5]
Deng WG, Saunders MA, Gilroy DW, He XZ, Yeh H, et al. (2002) Purification and characterization of a cyclooxygenase-2 and angiogenesis suppressing factor produced by human fibroblasts. FASEB J 16: 1286–1288. doi: 10.1096/fj.01-0844fje
[6]
Cheng HH, Kuo CC, Yan JL, Chen HL, Lin WC, et al. (2012) Control of cyclooxygenase-2 expression and tumorigenesis by endogenous 5-methoxytryptophan. Proc Natl Acad Sci U S A 109: 13231–13236. doi: 10.1073/pnas.1209919109
[7]
Schroer K, Zhu Y, Saunders MA, Deng WG, Xu XM, et al. (2002) Obligatory role of cyclic adenosine monophosphate response element in cyclooxygenase-2 promoter induction and feedback regulation by inflammatory mediators. Circulation 105: 2760–2765. doi: 10.1161/01.cir.0000018127.10968.34
[8]
Saunders MA, Sansores-Garcia L, Gilroy DW, Wu KK (2001) Selective suppression of CCAAT/enhancer-binding protein beta binding and cyclooxygenase-2 promoter activity by sodium salicylate in quiescent human fibroblasts. J Biol Chem 276: 18897–18904. doi: 10.1074/jbc.m011147200
[9]
Thompson PR, Wang D, Wang L, Fulco M, Pediconi N, et al. (2004) Regulation of the p300 HAT domain via a novel activation loop. Nat Struct Mol Biol 11: 308–315. doi: 10.1038/nsmb740
[10]
Wang L, Tang Y, Cole PA, Marmorstein R (2008) Structure and chemistry of the p300/CBP and Rtt109 histone acetyltransferases: implications for histone acetyltransferase evolution and function. Curr Opin Struct Biol 18: 741–747. doi: 10.1016/j.sbi.2008.09.004
[11]
Goodman RH, Smolik S (2000) CBP/p300 in cell growth, transformation, and development. Genes Dev 14: 1553–1577.
[12]
Grunstein M (1997) Histone acetylation in chromatin structure and transcription. Nature 389: 349–352. doi: 10.1038/38664
[13]
Deng WG, Zhu Y, Wu KK (2003) Up-regulation of p300 binding and p50 acetylation in tumor necrosis factor-alpha-induced cyclooxygenase-2 promoter activation. J Biol Chem 278: 4770–4777. doi: 10.1074/jbc.m209286200
[14]
Deng WG, Zhu Y, Wu KK (2004) Role of p300 and PCAF in regulating cyclooxygenase-2 promoter activation by inflammatory mediators. Blood 103: 2135–2142. doi: 10.1182/blood-2003-09-3131
[15]
Mantelingu K, Reddy BA, Swaminathan V, Kishore AH, Siddappa NB, et al. (2007) Specific inhibition of p300-HAT alters global gene expression and represses HIV replication. Chem Biol 14: 645–657. doi: 10.1016/j.chembiol.2007.04.011
[16]
Smith JL, Freebern WJ, Collins I, De Siervi A, Montano I, et al. (2004) Kinetic profiles of p300 occupancy in vivo predict common features of promoter structure and coactivator recruitment. Proc Natl Acad Sci U S A 101: 11554–11559. doi: 10.1073/pnas.0402156101
[17]
Martin P (1997) Wound healing–aiming for perfect skin regeneration. Science 276: 75–81. doi: 10.1126/science.276.5309.75
[18]
Sartore S, Chiavegato A, Faggin E, Franch R, Puato M, et al. (2001) Contribution of adventitial fibroblasts to neointima formation and vascular remodeling: from innocent bystander to active participant. Circ Res 89: 1111–1121. doi: 10.1161/hh2401.100844
[19]
Barnes PJ, Adcock IM, Ito K (2005) Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Respir J 25: 552–563. doi: 10.1183/09031936.05.00117504
[20]
Gayther SA, Batley SJ, Linger L, Bannister A, Thorpe K, et al. (2000) Mutations truncating the EP300 acetylase in human cancers. Nat Genet 24: 300–303. doi: 10.1038/73536
[21]
Iyer NG, Ozdag H, Caldas C (2004) p300/CBP and cancer. Oncogene 23: 4225–4231. doi: 10.1038/sj.onc.1207118
[22]
McKinsey TA, Olson EN (2004) Cardiac histone acetylation–therapeutic opportunities abound. Trends Genet 20: 206–213. doi: 10.1016/j.tig.2004.02.002
[23]
Morimoto T, Sunagawa Y, Kawamura T, Takaya T, Wada H, et al. (2008) The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. J Clin Invest 118: 868–878. doi: 10.1172/jci33160
[24]
Balasubramanyam K, Swaminathan V, Ranganathan A, Kundu TK (2003) Small molecule modulators of histone acetyltransferase p300. J Biol Chem 278: 19134–19140. doi: 10.1074/jbc.m301580200
[25]
Mai A, Rotili D, Tarantino D, Ornaghi P, Tosi F, et al. (2006) Small-molecule inhibitors of histone acetyltransferase activity: identification and biological properties. J Med Chem 49: 6897–6907. doi: 10.1021/jm060601m
[26]
Deng WG, Zhu Y, Montero A, Wu KK (2003) Quantitative analysis of binding of transcription factor complex to biotinylated DNA probe by a streptavidin-agarose pulldown assay. Anal Biochem 323: 12–18. doi: 10.1016/j.ab.2003.08.007
[27]
Wu KK (2006) Analysis of protein-DNA binding by streptavidin-agarose pulldown. Methods Mol Biol 338: 281–290. doi: 10.1385/1-59745-097-9:281
